3 completed, 1 terminated. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 3 | Completed 3 |
Follow labetuzumab: new trials by email Literature Review of labetuzumab trials Research Report on labetuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer hMN14 (labetuzumab) - Colorectal Cancer, Colon Cancer | Phase 1 / Phase 2 | Completed | Gilead Sciences | 30 | 2000-02-01 | 2021-08-19 |
| Safety Study of 90Y-hMN14 to Treat Colorectal Cancer hMN14 (labetuzumab) - Colorectal Cancer, Colon Cancer | Phase 1 / Phase 2 | Completed | Gilead Sciences | 72 | 2000-01-01 | 2021-08-19 |
| Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer hMN14 (labetuzumab) - Pancreatic Neoplasms | Phase 1 / Phase 2 | Completed | Gilead Sciences | 75 | 2000-01-01 | 2021-08-19 |
| Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery hMN14 (labetuzumab) - Colorectal Neoplasms | Phase 1 | Terminated | Gilead Sciences | 30 | 2021-08-19 |
Colonic Neoplasms (3) · Colorectal Neoplasms (3) · Rectal Neoplasms (3) · Breast Neoplasms (1) · Pancreatic Neoplasms (1)
Gilead Sciences (4)
United States (4) · Germany (2) · Hungary (2) · Netherlands (1) · Sweden (1) · Switzerland (1)
Lauri Welles, MD (2) · Terence Rugg, MD (2) · William Wegener, MD (2)